

Haematologica
HAEMATOL/2019/235648
Version 3

Ruxolitinib and interferon- α 2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.

Anders Lindholm Sørensen, Stine Ulrik Mikkelsen, Trine Alma Knudsen, Mads Emil Bjørn, Christen Lykkegaard Andersen, Ole Weis Bjerrum, Nana Brochmann, Dustin Andersen Patel, Lise Mette Rahbek Gjerdrum, Daniel El Fassi, Torben A. Kruse, Thomas Stauffer Larsen, Hans Torben Mourits-Andersen, Claus Henrik Nielsen, Christina Ellervik, Niels Pallisgaard, Mads Thomassen, Lasse Kjær, Vibe Skov, and Hans Carl Hasselbalch

Disclosures: Novartis Oncology supplied the ruxolitinib used in the trial. SUM and NP have received travel grants from Novartis Oncology. HCH, CHN, NP and MEB have received research funding from Novartis Oncology. NP is in the Novartis Speakers Bureau. OWB, DEF and CHN have conducted educational activities for Novartis.

Contributions: Conceptualization: HCH, CLA, OW, DEF, TK, TSL, CHN, NP. Investigators and sub-investigators: HCH, HTMA, TSL, NB, ALS, SUM, MEB, TAK, LK, VS. Data analyses: ALS. Writing of the first draft: ALS, HCH. Review and editing: all authors.